Sarclisa Injection, Solution, Concentrate
Product Images NDC 0024-0654

5 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sarclisa (NDC 0024-0654). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (A0473462 6f9d 4eca A5bf 8620aea68e8a 01)

Figure 1 (A0473462 6f9d 4eca A5bf 8620aea68e8a 01)
A Kaplan-Meier survival curve illustrating progression-free survival (PFS) probability over 16 months comparing two treatment regimens, Isa-Pd and Pd. The vertical axis represents PFS probability, and the horizontal axis shows time in months. Isa-Pd shows higher PFS probability over time versus Pd, supported by median PFS values and hazard ratio data table with statistical significance (P = 0.001). A patient risk table is included below the graph.*
FDA Label Image

Figure 2 (A0473462 6f9d 4eca A5bf 8620aea68e8a 02)

Figure 2 (A0473462 6f9d 4eca A5bf 8620aea68e8a 02)
A progression-free survival (PFS) probability curve over 24 months comparing Isa-Kd and Kd treatment groups. The graph includes median months and hazard ratios with confidence intervals in a table, patient risk numbers at different time points, and p-value indicating statistical significance.*
FDA Label Image

Figure 3 (A0473462 6f9d 4eca A5bf 8620aea68e8a 03)

Figure 3 (A0473462 6f9d 4eca A5bf 8620aea68e8a 03)
A Kaplan-Meier survival curve chart illustrating progression-free survival (PFS) probability over time in months for two treatment groups: Isa-VRd (isatuximab combined with VRd) and VRd alone. The chart includes median PFS values, hazard ratio, confidence interval, and p-value. Patient counts at risk are displayed below the time axis for both groups.*
FDA Label Image

Principal Display Panel (100 mg/5 mL Vial Carton)

Principal Display Panel (100 mg/5 mL Vial Carton)
The packaging label for Sarclisa (isatuximab-irfc) Injection, 100 mg/5 mL (20 mg/mL), an intravenous infusion concentrate. The label indicates one single-dose vial, with instructions to discard unused portions. The manufacturer is Sanofi-Aventis U.S. LLC, Morristown, NJ. The label includes storage instructions and states the product is preservative-free and sterile.*
FDA Label Image

Principal Display Panel (500 mg/25 mL Vial Carton)

Principal Display Panel (500 mg/25 mL Vial Carton)
Box label for Sarclisa (isatuximab-irfc) injection concentrate, 500 mg/25 mL (20 mg/mL) for intravenous infusion after dilution. The label states it contains one single-dose vial, is manufactured by Sanofi-Aventis U.S. LLC, and includes storage instructions at 36°F-46°F (2°C-8°C). The packaging also lists inactive ingredients and cautions such as no preservatives and to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.